• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Oragenics Inc. Common Stock (NY:OGEN)

    0.4991 -0.0109 (-2.14%)
    Streaming Delayed Price Updated: 12:50 PM EDT, Sep 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Oragenics Inc. Common Stock

    < Previous 1 2 3 4 Next >
    NetworkNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Advances Phase IIa Concussion Trial, Provides FDA and Listing Updates
    Via Investor Brand Network
    BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Activates All Australian Phase IIa Trial Sites for ONP-002
    Via Investor Brand Network
    News headline image
    Sidoti Events, LLC's May Micro-Cap Virtual Conference
    Via ACCESS Newswire
    InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) to Present at Sidoti Micro-Cap Virtual Investor Conference
    Via Investor Brand Network
    BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Highlights Phase IIa Progress and Strategic CNS Expansion Plans
    Via Investor Brand Network
    InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Signs LOI to License CardioDialysis Technology From Sigyn Therapeutics
    Via Investor Brand Network
    BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Advances Phase IIa Trial Enrollment For Concussion Treatment Candidate
    Via Investor Brand Network
    BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Reports Early Dosing Progress in Phase IIa Trial of Intranasal Concussion Therapy
    Via Investor Brand Network
    BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Doses First Patient in Phase IIa Trial of Concussion Treatment
    Via Investor Brand Network
    InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Reports Going Concern Audit Opinion Disclosure
    Via Investor Brand Network
    TinyGemsBreaks – Oragenics Inc. (NYSE American: OGEN) Files 2025 Form 10-K And Provides Operational Update
    Via Investor Brand Network
    InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Initiates First Clinical Site for Phase IIa Trial of ONP-002 in Australia
    Via Investor Brand Network
    BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Explores CNS Asset Acquisitions To Expand Brain Health Pipeline
    Via Investor Brand Network
    InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Receives Australian Ethics Approval to Launch Phase IIa Concussion Trial
    Via Investor Brand Network
    BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Previews 2026 Milestones for Intranasal Concussion Therapeutic ONP-002
    Via Investor Brand Network
    BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Engages DUCK FLATS Pharma for IND Readiness and Regulatory Execution
    Via Investor Brand Network
    BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Participates in SCOPE Summit 2026 Ahead of Phase 2a Concussion Trial
    Via Investor Brand Network
    BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) to Present at Sequire Investor Summit 2026
    Via Investor Brand Network
    BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Regains NYSE Compliance, Advances Toward First Clinical Trial and Expands AI-Driven Neurology Pipeline
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Oragenics Q3 2025 Shareholder Update
    From Oragenics, Inc.
    Via Business Wire
    BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Regains NYSE Compliance, Strengthens Balance Sheet for Clinical Advancement
    Via Investor Brand Network
    News headline image
    Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
    From Oragenics, Inc.
    Via Business Wire
    InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Partners with Receptor.AI to Accelerate AI-Driven Discovery of Brain-Targeted Therapeutics
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development
    From Oragenics
    Via Business Wire
    InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Highlights Q2 2025 Progress and Prepares for Phase IIa Concussion Trial
    Via Investor Brand Network
    InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Selects Southern Star Research as CRO for Phase IIa Trial of Intranasal Concussion Therapy ONP-002
    Via Investor Brand Network
    InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Secures U.S. Manufacturing Partner Ahead of Phase IIb Trials for Concussion Drug
    Via Investor Brand Network
    InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Secures $16.5 Million in Preferred Stock Offering to Advance Intranasal Concussion Therapy
    Via Investor Brand Network
    BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Announces $20 Million Preferred Stock and Warrant Offering
    Via Investor Brand Network
    InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) to Spotlight Concussion Candidate at BIO 2025 and Neurotrauma Symposium
    Via Investor Brand Network
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.